AHR; AHR, aryl hydrocarbon receptor; ALT, alanine transaminase; ANOVA, analysis of variance; AST, aspartate transaminase; AUC, area under the curve; CAR, constitutive androstane receptor; CD36, cluster of differentiation 36; CYP, cytochrome P450; EPF, enrichment by protein function; Endocrine disruption; Environmental liver disease; FDR, false discovery rate; FGF21, fibroblast growth factor 21; GCR, glucocorticoid receptor; GO, gene ontology; H&E, hematoxylin-eosin; HDL, high-density lipoprotein; HFD, high fat diet; IGF1, insulin-like growth factor 1; IL-6, interleukin 6; IPF, interaction by protein function; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant protein-1; MUP, major urinary protein; NAFLD, non-alcoholic fatty liver disease; NFKBIA, nuclear factor kappa-inhibitor alpha; Nonalcoholic fatty liver disease; PAI-1, plasminogen activator inhibitor-1; PCB, polychlorinated biphenyl; PCB126; PLIN2, perilipin-2; PNPLA3, patatin-like phospholipase domain-containing protein 3; PPARα, peroxisome proliferator-activated receptor alpha; PXR, pregnane-xenobiotic receptor; Perilipin-2; Pheromones; SGK1, serum/glucocorticoid regulated kinase; TAFLD, toxicant-associated fatty liver disease; TASH, toxicant-associated steatohepatitis; TAT, tyrosine aminotransferase; TMT, tandem mass tag; VLDL, very low-density lipoprotein; WT, wild type; ZFP125, zinc finger protein 125; miR, microRNA; nHDLc, non-HDL cholesterol